TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib

被引：0
|
作者：
Meraz, I. [1 ]
Majidi, M. [1 ]
Gao, L. [1 ]
Ren, C. [1 ]
Wu, S. [1 ]
Song, R. [1 ]
Meng, F. [1 ]
Xu, Y. [1 ]
Wang, Q. [2 ]
Xi, Y. [2 ]
Wang, J. [2 ]
Jung, S. Y. [3 ]
Shpall, E. [4 ]
Roth, J. A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Bioinformat & Computat Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Biochem, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB372
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC.
    Meraz, Ismail M.
    Majidi, Mourad
    Shao, RuPing
    Gao, Lihui
    Feng, Meng
    Chen, Huiqin
    Ha, Min Jin
    Roth, Jack A.
    CANCER RESEARCH, 2021, 81 (13)
  • [2] KRAS mutant gene editing prevents tumor growth in vivo and overcomes acquired resistance to KRASG12C inhibitor
    Divita, Gilles
    Guzman-Gonzales, Veronica
    Grunenberger, Audrey
    Czuba, Elodie
    Guidetti, Melanie
    Josserand, Veronique
    Desai, Neil
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification
    Solanki, Hitendra S.
    Imbody, Denis
    Desai, Bina
    Kato, Ryoji
    Stewart, Paul A.
    Stern, Yaakov
    Majumder, Anurima
    Bridenstine, Liznair
    Sarca, Bhaswati
    Miroshnychenko, Dada
    Aronchik, Ida
    Marusyk, Andriy
    Haura, Eric B.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [4] KRAS Mutant Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired Resistance to KRASG12C and KRASG12D Small Molecule Inhibitors
    Desai, Neil
    Grunenberger, Audrey
    Guzman-Gonzalez, Veronica
    Cabrera, Lea
    Czuba, Elodie
    Faure, Virginie
    Josserand, Veronique
    Di Vita, Gilles
    MOLECULAR THERAPY, 2024, 32 (04) : 226 - 226
  • [5] Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3KmTOR pathway inhibition and regulated by 4E-BP1
    Meraz, Ismail M.
    Wu, Shuhong
    Majidi, Mourad
    Ren, Chenghui
    Xu, Yi
    Meng, Feng
    Gao, Lihui
    Song, Renduo
    Zhang, Ran
    Fang, Bingliang
    Wang, Qi
    Xi, Yuanxin
    Wang, Jing
    Jung, Sung Yun
    Roth, Jack A.
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Acquired Resistance to KRASG12C Inhibition in Cancer
    Awad, M. M.
    Liu, S.
    Rybkin, I. I.
    Arbour, K. C.
    Dilly, J.
    Zhu, V. W.
    Johnson, M. L.
    Heist, R. S.
    Patil, T.
    Riely, G. J.
    Jacobson, J. O.
    Yang, X.
    Persky, N. S.
    Root, D. E.
    Lowder, K. E.
    Feng, H.
    Zhang, S. S.
    Haigis, K. M.
    Hung, Y. P.
    Sholl, L. M.
    Wolpin, B. M.
    Wiese, J.
    Christiansen, J.
    Lee, J.
    Schrock, A. B.
    Lim, L. P.
    Garg, K.
    Li, M.
    Engstrom, L. D.
    Waters, L.
    Lawson, J. D.
    Olson, P.
    Lito, P.
    Ou, S. -H. I.
    Christensen, J. G.
    Janne, P. A.
    Aguirre, A. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25): : 2382 - 2393
  • [7] Vertical inhibition overcomes adaptive resistance to KRASG12C inhibition
    Ryan, Meagan B.
    de la Cruz, Ferran Fece
    Phat, Sarah
    Myers, David T.
    Shahzade, Heather A.
    Hong, Catriona B.
    Corcoran, Ryan B.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [8] Understanding the basis for acquired resistance to KRASG12C inhibitors
    Santos Ramos, A.
    Gomez Sanchez, D.
    Rico Lopez, S.
    Plaza Exposito, P.
    Paz-Ares, L.
    Ferrer Sanchez, I.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1411 - S1411
  • [9] Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer
    Lee, J. W.
    Kim, S.
    Cruz-Gomez, S.
    Yang, C.
    Burtness, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S48 - S48
  • [10] Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors
    Favata, Margaret
    Weber, Michael
    Abdollahi, Angela
    Roman, Valerie Dostalik
    Farren, Matt
    Gilmartin, Aidan
    Kim, Sunkyu
    Wee, Susan
    Rios-Doria, Jonathan
    CANCER RESEARCH, 2023, 83 (07)
12345